This study reported clinical results of patients with locally advanced cervical cancer who treated with radiotherapy and image-guided adapted brachytherapy and combinations of cytotoxic drugs. Material and Methods: This study included 190 patients with cervical cancer IIb, IIIb, IVb (metastases in para-aortic lymph nodes) during 2011-2015 treated with external-beam radiotherapy or chemoradiotherapy, total dose for D95 50Gy for 25 fractions following Image-guided brachytherapy HDR with prescribing dose for CTV-HR D90 7.5 Gy weekly 4 fractions. Total dose CTV-HR D90 40 Gy (EQD2). Total dose for HR-CTV D90 was 95.0 ± 0.67 Gy (EQD2). Presented group A (n = 72) -radiation therapy, B (n = 40) -chemoradiation therapy with cisplatin C (n = 39) -chemoradiation therapy with a combination of irinotecan + cisplatin, 2 courses of adjuvant chemotherapy D (n = 39) -chemoradiation therapy with a combination of paclitaxel + cisplatin, 2 courses of adjuvant chemotherapy. Clinical outcomes including local control (LC), cancer-specific survival (CSS), overall survival (OS), and toxicity were analyzed.